Plasma half-life extension of small recombinant antibodies by fusion to immunoglobulin-binding domains

J Biol Chem. 2012 Feb 10;287(7):4462-9. doi: 10.1074/jbc.M111.311522. Epub 2011 Dec 6.

Abstract

Many therapeutic proteins possessing a small size are rapidly cleared from circulation. Half-life extension strategies have therefore become increasingly important to improve the pharmacokinetic and pharmacodynamic properties of protein therapeutics. Here, we performed a comparative analysis of the half-life extension properties of various bacterial immunoglobulin-binding domains (IgBDs) derived from Staphylococcus protein A (SpA), Streptococcus protein G (SpG), and Finegoldia (formerly Peptostreptococcus) protein L (PpL). These domains, composed of 50-60 amino acid residues, were fused to the C terminus of a single-chain Fv and a bispecific single-chain diabody, respectively. All fusion proteins were produced in mammalian cells and retained their antigen-binding properties. The half-lives of the antibody molecules were prolonged to varying extents for the different IgBDs. The strongest effects in mice were observed for domain C3 of SpG (SpG(C3)) followed by domains B and D of SpA, suggesting that SpG(C3) is particularly useful to extend the plasma half-life of small proteins.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Bacterial Proteins / genetics
  • Bacterial Proteins / pharmacokinetics*
  • Bacterial Proteins / pharmacology
  • Half-Life
  • Humans
  • Jurkat Cells
  • Mice
  • Protein Structure, Tertiary
  • Recombinant Fusion Proteins / genetics
  • Recombinant Fusion Proteins / pharmacokinetics*
  • Recombinant Fusion Proteins / pharmacology
  • Single-Chain Antibodies / genetics
  • Single-Chain Antibodies / pharmacokinetics*
  • Single-Chain Antibodies / pharmacology

Substances

  • Bacterial Proteins
  • Recombinant Fusion Proteins
  • Single-Chain Antibodies